Company / Revenue
NOVAVAX INC Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.1B
FY2025
5-year range
$475.6M / $1.1B
FY2021-FY2025
Trend
+64.7%
vs FY2024
Sector context
#39 of 155
Health Care
What the data says
NOVAVAX INC's revenue of $1.1B is higher than 75% of companies in the Health Care sector (FY2025). Revenue has fluctuated over the past 10 years, ranging from $15M in FY2018 to $1.1B in FY2021.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +18.8%. Top quartile in the Health Care sector.
Improved from $984M to $1.1B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +33.2%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 155This company $1.1B Sector average $4.5B
▼
-74.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.8%, indicating consistent growth.
- In FY2025, revenue increased 64.7% year-over-year.
- Ranks #39 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +64.7% |
| FY2024 | $682.2M | -30.7% |
| FY2023 | $983.7M | +106.8% |
| FY2022 | $475.6M | -58.5% |
| FY2021 | $1.1B | +141.0% |
| FY2020 | $475.6M | +1425.5% |
| FY2019 | $31.2M | +103.1% |
| FY2018 | $15.4M | -57.6% |
| FY2017 | $36.3M | +18.2% |
| FY2016 | $30.7M | +46.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026